



OPEN ACCESS

EDITED AND REVIEWED BY

Jessica K. Roberts,
Cognigen, United States

*CORRESPONDENCE

Lu Chen,
✉ 50796877@qq.com
Dongke Yu,
✉ yudongke@med.uestc.edu.cn
Chun Guo,
✉ chunguo11@hotmail.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 09 August 2023

ACCEPTED 16 August 2023

PUBLISHED 23 August 2023

CITATION

Shi J, Tan X, Feng G, Yuan Z, Jiang Z, Banda S, Wang L, Zheng W, Chen L, Yu D and Guo C (2023), Corrigendum: Research advances in drug therapy of endometriosis.
Front. Pharmacol. 14:1274946.
doi: 10.3389/fphar.2023.1274946

COPYRIGHT

© 2023 Shi, Tan, Feng, Yuan, Jiang, Banda, Wang, Zheng, Chen, Yu and Guo. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Research advances in drug therapy of endometriosis

Jianguo Shi^{1,2†}, Xin Tan^{1,2†}, Guimei Feng^{3,4†}, Zhou Yuan⁵, Zhongliang Jiang⁶, Srikanth Banda⁷, Lin Wang⁸, Wei Zheng⁵, Lu Chen^{1,2*}, Dongke Yu^{1,2*} and Chun Guo^{3,4*}

¹Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, ²Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, ³Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, ⁴Chinese Academy of Sciences Sichuan Traditional Medicine Research Hospital, Chengdu, China, ⁵Pharmacy College, Chengdu University of Translational Chinese Medicine, Chengdu, China, ⁶Miller School of Medicine, University of Miami, Miami, FL, United States, ⁷Department of Chemistry and Biochemistry, Florida International University, Miami, FL, United States, ⁸College of Food and Bioengineering, Xihun University, Chengdu, China

KEYWORDS

endometriosis, pathogenesis, medical treatment, gonadotropin-releasing antagonist, aromatase inhibitor

A Corrigendum on Research advances in drug therapy of endometriosis

by Shi J, Tan X, Feng G, Zhuo Y, Jiang Z, Banda S, Wang L, Zheng W, Chen L, Yu D and Guo C (2023). *Front. Pharmacol.* 14:1199010. doi: 10.3389/fphar.2023.1199010

In the published article, there was an error in [Figure 5](#) as published. In [Figure 5](#), the structure and name of the compound are incorrect. The corrected [Figure 5](#) appears below.

In the published article, the reference for [Donnez et al., 1994](#) was incorrectly written as “Donnez, J., Nisolle, M., Clerckx, F., Casanas-Roux, F., Saussoy, P., and Gillerot, S. (1994). Advanced endoscopic techniques used in dysfunctional bleeding, fibroids and endometriosis, and the role of gonadotrophin-releasing hormone agonist treatment. *Br J Obstet Gynaecol* 101 Suppl 10, 2-9. doi: 10.1111/j.1471-0528.1994.tb13677.x.” It should be deleted.


In the published article, the reference for [Carr et al., 2014](#) was incorrectly written as “Carr, B., Dmowski, W.P., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., et al. (2014). Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. *Reprod Sci* 21(11), 1341-1351. doi: 10.1177/1933719114549848.” It should be deleted.

In the published article, the reference for [Donnez et al., 2020](#) was incorrectly written as “Donnez, J., Taylor, H.S., Taylor, R.N., Akin, M.D., Tatarchuk, T.F., Wilk, K., et al. (2020). Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. *Fertil Steril* 114(1), 44-55. doi: 10.1016/j.fertnstert.2020.02.114.” It should be deleted.

A correction has been made to the **Heading** of [3.3.3](#). This heading previously stated: “3.3.3 Linzagolix”

The corrected sentence appears below:

“3.3.3 BAY1214784”



A correction has been made to 3.3.3, paragraph 1. This sentence previously stated:

“Linzagolix (Figure 5) is an oral effective and highly selective hGnRH-A.”

The corrected sentence appears below:

“BAY1214784 (Figure 5) is an oral effective and highly selective hGnRH-A.”

A correction has been made to 3.3.3, paragraph 2. This sentence previously stated:

The pharmacokinetics studies further demonstrated BAY1214784 exhibits excellent features *in vivo* including an appropriate half-life of 15–18 h, high oral bioavailability, small amount of distribution, zero food effect, and no interaction with transporters or CYP3A4 enzymes (Donnez et al., 1994; Carr et al., 2014). Donnez et al. (Donnez et al., 2020) investigated the effect of BAY1214784 on treating endometriosis-related pain (EAP). The results showed that compared with placebo,

BAY1214784 significantly alleviated the endometriosis-associated pain in the patients.

The sentences below need to be deleted. After the above sentences are deleted, the last sentence of paragraph 2 is merged into the first paragraph.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.